30 closest matches · ranked by relevance
Critically Ill Renal Failure Requiring CVVHD and Oseltamivir · Critically Ill Requiring ECMO and Oseltamivir
Primary: Continuous Venovenous Hemodialysis (CVVHD)Oseltamivir Carboxylate Transmembrane Clearance — 52.2; 43.3 mL/min
End Stage Renal Disease
Primary: Maximum Plasma Concentration (Cmax) of Oseltamivir in HD Participants During Days 1 to 5 — 20.2 ng/mL
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
Influenza
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants
Bacterial Infections
Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Influenza A
Primary: Clinical Status of Participants on Day 7 — 1; 1; 2; 1 Participants — p=0.181
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460
Critical COVID-19 With Respiratory Failure · Acute Respiratory Distress Syndrome (ARDS) · Corona Virus Infection
Primary: Resolution of Respiratory Failure (Alive and Free of Respiratory Failure) — 72; 33 Participants
Healthy Volunteer
Primary: Total Dialysate Clearance for Automated Peritoneal Dialysis (CLDAPD) of Oseltamivir and Oseltamivir Carboxylate for 75 mg Dose — NA; NA; 0.183; 0.230 Litre (L)/hour (h)
Influenza
Primary: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Plasma Concentration (AUClast) of Oseltamivir and Oseltamivir Carboxylate on Day 1…
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Influenza
Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306
Venous Thromboembolism
Primary: To Determine if an Adjusted-dose of Fondaparinux 2.5 mg Subcutaneously (SQ) q48 hr in Critically Ill Patients With Renal Failure Will Achieve Peak and Trough Levels…
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Influenza
Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…
Aspergillosis; Pulmonary, Invasive (Etiology)
Primary: Number of Participants With IAA-infection at ICU Discharge — 2; 4 Participants
Influenza, Human
Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25
Influenza
Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants
Influenza, Human
Primary: Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug…
Respiratory Failure
Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants
Influenza
Primary: Number of Participants With Laboratory-Confirmed Clinical Influenza, ITT Population — 7; 5 participants — p=0.772
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
COVID · Severe Acute Respiratory Syndrome · Sars-CoV2
Primary: To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per…
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Influenza
Primary: Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption — 1; 1; 1 number of participants with AEs